9/19/2011 7:45:30 AM
French drugmaker Sanofi has scored an important victory in a patent dispute with Sun Pharmaceuticals that will keep generic copies of its Eloxatin colon cancer drug off the United States market until August 2012. A ruling by the U.S. District Court for the District of New Jersey maintained Sanofi's market exclusivity for Eloxatin in the United States through Aug. 9, 2012, Sanofi said in a statement on Monday. Mumbai-based Sun had appealed an April 2010 ruling requiring the Indian company to stop selling its generic version of Eloxatin as of June 30, 2010, Sanofi said.
comments powered by